Related Experiment Video

Updated: Aug 16, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors

Laura Cucinotta1, Alessia Filippone1, Giovanna Casili1

  • 1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy.

International Journal of Molecular Sciences
|December 23, 2022
PubMed

Insights

Protein phosphatase 2A (PP2A) is crucial for cell growth and its dysregulation is linked to cancer. Inhibiting CIP2A, a PP2A regulator, shows promise as a targeted cancer therapy, particularly for brain tumors like glioblastoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein phosphatase 2A (PP2A) is a key regulator of cellular processes.
  • PP2A dysregulation is implicated in human diseases, including cancer.
  • PP2A's tumor suppressor role and involvement in cell growth control are established.

Purpose of the Study:

  • To review the literature on PP2A's role in brain tumors, specifically gliomas and glioblastoma (GBM).
  • To explore the potential of PP2A inhibitors, with a focus on CIP2A inhibition, for cancer therapy.
  • To evaluate CIP2A inhibition as a targeted oncology strategy.

Main Methods:

  • Literature review and analysis of existing research on PP2A in brain tumors.
  • Focus on the role of PP2A inhibitors, specifically targeting CIP2A.
  • Examination of CIP2A's mechanisms in promoting tumor cell growth.

Main Results:

  • PP2A is essential for controlling cell growth and its dysregulation contributes to cancer development.
  • CIP2A promotes tumor cell growth by enhancing survival, proliferation, and inhibiting apoptosis.
  • CIP2A inhibition emerges as a significant strategy in oncology.

Conclusions:

  • Targeted inhibition of CIP2A presents a promising therapeutic strategy for brain tumors.
  • Combination therapy involving PP2A inhibition and radiotherapy warrants further investigation.
  • Understanding PP2A's role is vital for developing novel cancer treatments.
Keywords:
CIP2A inhibitionGBMPP2APP2A inhibitorsbrain tumorscancer

More Related Videos

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

6.8K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

447

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K